VMAT2 Inhibitors for Huntington's Disease Chorea
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">vmat2-inhibitors</th>
</tr>
<tr>
<td class="label">Adverse Effect</td>
<td>Tetrabenazine</td>
</tr>
<tr>
<td class="label">Somnolence/sedation</td>
<td>~31%</td>
</tr>
<tr>
<td class="label">Depression</td>
<td>~19%</td>
</tr>
<tr>
<td class="label">Insomnia</td>
<td>~18%</td>
</tr>
<tr>
<td class="label">Akathisia</td>
<td>~10%</td>
</tr>
<tr>
<td class="label">Parkinsonism</td>
<td>~15%</td>
</tr>
<tr>
<td class="label">Dosing frequency</td>
<td>3× daily</td>
</tr>
<tr>
<td class="label">CYP2D6 genotyping</td>
<td>Required</td>
</tr>
</table>
Introduction
Overview
Vesicular monoamine transporter 2 (VMAT2) inhibitors are the primary pharmacological treatment for chorea associated with [Huntington's disease](/mechanisms/huntington-pathway) (HD). [@vmat2022]
This class includes tetrabenazine (Xenazine, approved 2008), deutetrabenazine (Austedo, approved 2017), and valbenazine (Ingrezza, [@vesicular]
approved 2023 for HD chorea). These agents reduce hyperkinetic involuntary movements by depleting presynaptic [dopamine](/entities/dopamine) stores through blockade of [@rodrigues2020]
VMAT2, the transporter responsible for packaging monoamine neurotransmitters into synaptic vesicles. VMAT2 inhibitors represent a symptomatic [@bates2015]
treatment approach — they do not modify disease progression but can significantly improve quality of life by reducing the severity of choreiform [@ross2011]
movements that impair daily function, gait stability, and swallowing safety [@vmat2022][@vesicular][@rodrigues2020]. [@huntington1996]
Huntington's Disease and Chorea
Pathophysiology of HD Chorea
[Huntington's disease](/mechanisms/huntington-pathway) is caused by a CAG trinucleotide repeat expansion in the [huntingtin](/proteins/huntingtin)/proteins/huntingtin) gene ([HTT](/proteins/htt-protein))], leading to a toxic [@guay2010]
gain-of-function polyglutamine protein that causes progressive neurodegeneration primarily affecting the striatum ([basal ganglia). The preferential [@fda2008]
loss of medium spiny [neurons](/entities/neurons) (MSNs) in the indirect pathway of the basal ganglia results in reduced inhibition of the external globus pallidus, [@huntington2006]
ultimately leading to excessive thalamocortical excitation and the characteristic involuntary choreiform movements [@bates2015][@ross2011]. [@frank2010]
Clinical Significance of Chorea
Chorea — involuntary, irregular, unpredictable, brief movements that flow from one body part to another — is the hallmark motor feature of HD. It [@fda2017]
affects approximately 90% of HD patients and can impair gait, balance, speech, and swallowing. Chorea severity is measured using the Unified [@claassen2017]
Huntington's Disease Rating Scale Total Maximal Chorea (UHDRS-TMC) score, which assesses involuntary movements across seven body regions (face, [@huntington2016]
buccal-oral-lingual, trunk, and four extremities) on a scale of 0–28 [@bates2015][@huntington1996]. [@fda2023]
Mechanism of Action
VMAT2 Function
VMAT2 is a transmembrane protein located on the membranes of synaptic vesicles within monoaminergic [neurons](/entities/neurons). It transports [dopamine](/entities/dopamine), [serotonin](/entities/serotonin), [@furr2023]
[norepinephrine](/entities/norepinephrine), and histamine from the neuronal cytoplasm into synaptic vesicles using the energy generated by a vesicular proton gradient [@neurocrine2023]
(H⁺-ATPase). Vesicular packaging protects monoamines from degradation by cytoplasmic monoamine oxidase (MAO) and makes them available for [@furr2024]
calcium-dependent exocytotic release during neurotransmission [@vmat2022][@guay2010]. [@zhang2025]
VMAT2 Inhibition
VMAT2 inhibitors bind to VMAT2 and block monoamine transport into synaptic vesicles. Monoamines that remain in the cytoplasm are rapidly degraded by [@deutetrabenazine]
MAO, leading to presynaptic depletion of dopamine and other monoamines. With reduced vesicular dopamine stores, less dopamine is released into the
synaptic cleft when [neurons](/entities/neurons) fire. In the context of HD chorea, reduced dopaminergic signaling in the striatum helps normalize the imbalanced
indirect pathway activity, thereby suppressing involuntary movements [@vmat2022][@guay2010].
The anti-choreic effect is primarily mediated through dopamine depletion, although concurrent reduction of other monoamines ([serotonin](/entities/serotonin), [norepinephrine) contributes to the side effect profile, particularly depression and sedation [@guay2010].
Individual Agents
Tetrabenazine (Xenazine)
Tetrabenazine was the first FDA-approved treatment specifically indicated for chorea associated with HD (approved August 2008). It was originally developed in the 1950s as an antipsychotic agent and has been used in various countries for decades before receiving FDA approval [@fda2008][@huntington2006].
Pharmacokinetics:
- Rapidly absorbed orally with extensive first-pass metabolism
- Metabolized by carbonyl reductase to the active metabolites alpha-dihydrotetrabenazine (α-HTBZ) and beta-dihydrotetrabenazine (β-HTBZ)
- α-HTBZ is further metabolized by CYP2D6; CYP2D6 poor metabolizers have higher drug exposure
- Short half-life (5–7 hours for active metabolites), requiring dosing three times daily
- Maximum recommended dose: 100 mg/day (75 mg/day in CYP2D6 poor metabolizers) [@fda2008][@huntington2006]
Pivotal trial (TETRA-HD):The Phase 3 TETRA-HD trial demonstrated a significant reduction in UHDRS-TMC score of 5.0 units with tetrabenazine versus 1.5 units with placebo (p <
0.0001) over 12 weeks. However, the study also documented significant rates of adverse effects including depression (19%), sedation/somnolence (31%),
insomnia (18%), and akathisia (10%) [@huntington2006][@frank2010].
Deutetrabenazine (Austedo)
Deutetrabenazine is a deuterated form of tetrabenazine, approved in April 2017 for HD chorea. The incorporation of deuterium (a stable,
non-radioactive isotope of hydrogen) at specific positions in the molecule creates stronger carbon-deuterium bonds that are more resistant to CYP2D6
metabolism. This results in more predictable pharmacokinetics, longer half-life, and more stable plasma drug levels compared to tetrabenazine [@fda2017][@claassen2017].
Pharmacokinetic advantages over tetrabenazine:
- Twice-daily dosing (vs. three times daily for tetrabenazine)
- More consistent systemic exposure with lower peak-to-trough fluctuations
- Maximum recommended dose: 48 mg/day (36 mg/day in CYP2D6 poor metabolizers)
- Reduced CYP2D6-dependent metabolism variability [@fda2017][@claassen2017]
Pivotal trial (FIRST-HD):The Phase 3 FIRST-HD trial randomized 90 patients with HD chorea to deutetrabenazine or placebo. At week 12, deutetrabenazine demonstrated a
significant improvement in UHDRS-TMC score (−4.4 vs. −1.9 for placebo; treatment difference −2.5; p = 0.002). Crucially, deutetrabenazine showed a
more favorable tolerability profile than tetrabenazine, with lower rates of somnolence (11% vs. ~31% for tetrabenazine historically), depression,
anxiety, and akathisia [@claassen2017][@huntington2016].
Valbenazine (Ingrezza)
Valbenazine was originally approved in 2017 for tardive dyskinesia and received FDA approval for HD chorea in August 2023 based on the KINECT-HD Phase
3 trial. Valbenazine is a prodrug that is metabolized to the active metabolite +-α-dihydrotetrabenazine, which selectively inhibits VMAT2
[@fda2023][@furr2023].
Key advantages:
- Once-daily dosing
- Dose range: 40–80 mg/day
- More selective VMAT2 inhibition profile
- No CYP2D6 genotyping required for dose adjustment (unlike tetrabenazine and deutetrabenazine) [@fda2023][@furr2023]
Pivotal trial (KINECT-HD):The Phase 3 KINECT-HD trial randomized 128 patients with HD chorea to valbenazine or placebo. At week 12, valbenazine showed a statistically
significant improvement in UHDRS-TMC score (−4.6 vs. −1.4 for placebo; difference −3.2; p < 0.0001). The most common adverse event was somnolence (16%
vs. 3% for placebo). Serious adverse events were infrequent and not drug-related [@furr2023][@neurocrine2023].
Long-term data (KINECT-HD2):
The open-label extension study KINECT-HD2 demonstrated sustained efficacy over 50 weeks, with improvements in TMC score observable as early as week 2 on the initial 40 mg dose and maintained at doses up to 80 mg. Valbenazine also improved patient-reported outcomes on the Huntington's Disease Health Index (HD-HI) [@furr2024].
Comparative Efficacy and Safety
A systematic review and meta-analysis of VMAT2 inhibitors for HD chorea found that all three agents significantly improved motor outcomes versus placebo. The pooled analysis demonstrated:
- UHDRS Total Motor Score (TMS): Mean difference −3.80 (95% CI −5.76 to −1.83; I² = 0%)
- Total Maximal Chorea (TMC): Mean difference −3.05 (95% CI −3.84 to −2.26; I² = 0%)
Evidence suggests similar efficacy across agents, with the primary differentiators being tolerability and dosing convenience [@zhang2025].
Comparative Tolerability
Deutetrabenazine and valbenazine have more favorable tolerability profiles compared to tetrabenazine, likely due to more stable plasma drug levels and
reduced peak concentrations [@vesicular][@huntington2016][@zhang2025].
Adverse Effects and Monitoring
Common Adverse Effects
All VMAT2 inhibitors share a class-related side effect profile stemming from monoamine depletion:
- Sedation/somnolence: Most common adverse effect; may limit dose titration
- Depression and suicidality: Due to [serotonin](/entities/serotonin) and [norepinephrine](/entities/norepinephrine) depletion; patients must be monitored for worsening mood, particularly given the high baseline depression rate in HD
- Parkinsonism: Excessive dopamine depletion can cause bradykinesia, rigidity, and gait disturbance
- Akathisia: Restlessness and inability to sit still
- Dysphagia: Worsening of swallowing difficulty, which is already compromised in HD [@vmat2022][@fda2008][@huntington2016]
Black Box Warning
Tetrabenazine and deutetrabenazine carry a black box warning regarding depression and suicidality. HD patients already have elevated suicide rates (estimated 4–6 times that of the general population), and monoamine depletion can further exacerbate depressive symptoms. Regular screening with validated depression instruments is essential [@fda2008][@fda2017].
CYP2D6 Pharmacogenomics
Tetrabenazine and deutetrabenazine are metabolized by CYP2D6, and patients who are CYP2D6 poor metabolizers (approximately 7–10% of Caucasians) have significantly higher drug exposure. CYP2D6 genotyping is recommended before initiating tetrabenazine (required) or deutetrabenazine (recommended) to guide dose limits. Concurrent use of strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) also reduces metabolism and may require dose adjustment [@fda2017][^20].
Prescribing Considerations
Agent selection: Deutetrabenazine or valbenazine are generally preferred over tetrabenazine as first-line agents due to better tolerability, simpler dosing, and more predictable pharmacokinetics.
Dose titration: All agents should be started at low doses and titrated gradually at weekly intervals to the minimum effective dose.
Depression screening: Baseline and ongoing depression assessment is mandatory. VMAT2 inhibitors are contraindicated in patients with untreated or inadequately treated depression or active suicidal ideation.
Drug interactions: Strong CYP2D6 inhibitors require dose reduction for tetrabenazine and deutetrabenazine. MAO inhibitors are contraindicated with all VMAT2 inhibitors due to risk of serotonin syndrome and hypertensive crisis.
Treatment interruption: If therapy is interrupted for >1 week (tetrabenazine) or >2 weeks (deutetrabenazine), re-titration is
necessary [@vmat2022][@fda2008][@fda2017].
Other Indications
Beyond HD chorea, VMAT2 inhibitors are used for:
- Tardive dyskinesia: Deutetrabenazine and valbenazine are FDA-approved for this indication
- Tourette syndrome: Off-label use of tetrabenazine
- Other hyperkinetic movement disorders: Hemiballismus, myoclonus, and tic disorders (off-label) [@vmat2022][@vesicular]
Future Directions
Research continues on next-generation VMAT2 modulators with improved selectivity and tolerability. Additionally, combination approaches using VMAT2 inhibitors alongside disease-modifying therapies (when available) may offer complementary benefits — VMAT2 inhibitors for symptomatic relief while disease-modifying agents target the underlying [huntingtin](/proteins/huntingtin) protein] pathology [@zhang2025].
See Also
- [Neurodegenerative Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Deep Brain Stimulation (DBS)](/therapeutics/deep-brain-stimulation)
Background
The study of Vmat2 Inhibitors For Huntington's Disease Chorea has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[VMAT-2 Inhibitors (deutetrabenazine, tetrabenazine, valbenazine]. U.S. Department of Veterans Affairs Formulary Advisory. April 2022, VA PDF (2022)
[Vesicular Monoamine Transporter 2 (VMAT2] Inhibitors. LiverTox. NCBI Bookshelf, NCBI (n.d.)
[Unknown, Rodrigues FB, Wild EJ. Huntington's Disease clinical trials corner: April 2020. J Huntingtons Dis. 2020;9(2):185-197. [DOI (2020)](https://doi.org/10.3233/JHD-200002)
[Bates GP, et al., Huntington's Disease. Nat Rev Dis Primers. 2015;1:15005. [DOI (2015)](https://doi.org/10.1038/nrdp.2015.5)
[Unknown, Ross CA, Tabrizi SJ. Huntington's Disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98. [DOI (2011)](https://doi.org/10.1016/S1474-4422(10)
[Unknown, Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136-142. [DOI (1996)](https://doi.org/10.1002/mds.870110204)
[Unknown, Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331-373. [DOI (2010)](https://doi.org/10.1016/j.amjopharm.2010.08.006)
[FDA. XENAZINE (tetrabenazine] Prescribing Information. Lundbeck Inc, FDA Label (2008)
[DOI:10.1212/01.wnl.0000198586.85250.13](https://doi.org/10.1212/01.wnl.0000198586.85250.13)
[Unknown, Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington's Disease. Neuropsychiatr Dis Treat. 2010;6:657-665. [DOI (2010)](https://doi.org/10.2147/NDT.S6430)
[FDA. AUSTEDO (deutetrabenazine] Prescribing Information. Teva Pharmaceuticals, FDA Label (2017)
[Claassen DO, et al., Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington's Disease. J Clin Mov Disord. 2017;4:3. [DOI (2017)](https://doi.org/10.1186/s40734-017-0051-5)
[DOI:10.1001/jama.2016.8655](https://doi.org/10.1001/jama.2016.8655)
[FDA. INGREZZA (valbenazine] Prescribing Information. Neurocrine Biosciences, FDA Label (2023)
[Furr Stimming E, et al, Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's Disease (KINECT-HD]: a phase 3, randomised, double-blind, placebo-controlled trial (2023)](/[DOI:10.1016/S1474-4422(23)(https://doi.org/10.1016/S1474-4422(23))
Unknown, Neurocrine Biosciences. KINECT-HD Phase 3 Study Results Published in The Lancet Neurology. May 2023. [PR Newswire (2023)
[Furr Stimming E, et al, Sustained chorea improvements with long-term, once-daily valbenazine in adults with Huntington's Disease (KINECT-HD2] (2024)](/[DOI:10.1212/WNL.0000000000211985)(https://doi.org/10.1212/WNL.0000000000211985))
[Zhang Y, et al., Efficacy and safety of VMAT-2 inhibitors and dopamine stabilizers for Huntington's chorea: a systematic review, meta-analysis, and trial sequential analysis. Front Pharmacol. 2025;16:1637577. [DOI (2025)](https://doi.org/10.3389/fphar.2025.1637577)
Unknown, Deutetrabenazine therapy and CYP2D6 genotype. Medical Genetics Summaries. NCBI Bookshelf. [NCBI (n.d.)